

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q90666

Keiichi KAWAGOE, et al.

Appln. No.: 10/551,414

Group Art Unit: 1626

Confirmation No.: 4000

Examiner: Rebecca L ANDERSON

Filed: September 30, 2005

For: HYDRAZONE DERIVATIVE

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith except for U.S. patents.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required. However since a Statement under 37 C.F.R. § 1.97(e) can be filed, it is herewith submitted.

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

U.S. Appln. No.: 10/551,414

Attorney Docket No.: Q90666

Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application (Canadian Office Action, Application No.: 2,521,056 issued July 19, 2010) indicating the degree of relevancy found by the foreign patent office for the listed references.

It is noted that one reference, WO 03/039548, submitted in an Information Disclosure Statement on June 12, 2007, corresponds to one reference, CA 2 465 746, submitted herewith.

Applicants note that nine references (WO 03/007962; WO 02/40025; WO 01/68611; WO 92/12135; US 6,489,512; US 3,013,013; EP 0,383,449; GB 1,112,220; and Moloney et al. J. Med. Chem.; 40 (15) 2347-2362, 1997) cited in the Canadian Action were previously submitted in an Information Disclosure Statement on June 12, 2007. Additionally, one reference (R.N. 4844-03-5, 15 Nov. 1984) cited in the Canadian Action was cited by the Examiner in the U.S. Office Action issued on August 27, 2009. Therefore these references are already of record and are not being submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

U.S. Appln. No.: 10/551,414

Attorney Docket No.: Q90666

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

/Jennifer M. Hayes/

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

**65565**

CUSTOMER NUMBER

---

Jennifer M. Hayes  
Registration No. 40,641

Date: September 9, 2010